No CrossRef data available.
We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
Anticoagulant Options in Heparin-induced Thrombocytopenia
Published online by Cambridge University Press: 01 January 1999
Heparin-induced thrombocytopenia (HIT) is an idiosyncratic drug reaction first reported in the literature in the 1940's. Two different types of HIT have been identified. Type I, also known as benign, early-onset thrombocytopenia, occurs in as many as 20% of patients receiving heparin and is characterized by up to a 30% reduction in baseline platelet counts during the first few days of therapy. Despite reductions in platelet count, most patients with this type of HIT have platelet values above 100 × 109 cells/L, and this condition usually resolves in a few days without further adverse sequelae.